A Phase I, Randomized, Placebo-controlled, Double-blind, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Two Formulations of ASC36 Injection for Subcutaneous Use in Adult Participants With Obesity or Are Overweight

Summary

This randomized, double-blind, placebo-controlled single ascending dose (SAD)/ multiple ascending dose (MAD) study is designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of Two Formulations of ASC36 injection

Eligibility

Age range

18–65 years

Sex

All

Healthy volunteers

No

Interventions

• Drug
  ASC36 Injection A, for subcutaneous use

  ASC36 Injection A is an investigational formulation of ASC36 administered by subcutaneous injection.

• Drug
  ASC36 Placebo Injection A, for subcutaneous use

  ASC36 Placebo Injection A is an placebo injection matching ASC36 Injection A.

• Drug
  ASC36 Injection B, for subcutaneous use

  ASC36 Injection B is an investigational formulation of ASC36 administered by subcutaneous injection.

• Drug
  ASC36 Placebo Injection B, for subcutaneous use

  ASC36 Placebo Injection B is an placebo injection matching ASC36 Injection B.

Locations (2)